Concentric Medical has obtained FDA 510(k) clearance for its Merci L6 Retriever, a device that restores blood flow to ischemic stroke patients. The Merci Retriever is designed to restore blood flow by engaging, capturing and removing blood clots. It is a shaped wire constructed of nitinol, a memory wire, which allows delivery of the Retriever in linear form using standard catheterization techniques. A small puncture in the groin is used to introduce the Merci Retriever into an artery leading to the brain. Upon reaching the targeted area, the Retriever returns to its original shape when deployed. The Merci L6 Retriever joins the L family of retrievers, incorporating a 2.7-mm cylindrical helix with attached filaments. The filaments provide an additional mechanism for securing the clot during retrieval.
If you enjoy this content, please share it with a colleague
FDA Clears Neurovascular Retriever for Use in Stroke Patients
Related Content
January 16, 2024 — Penumbra, Inc., a thrombectomy company, has recently secured CE Mark (Conformité Européenne) for its ...
The global thrombectomy devices market is poised to experience substantial expansion, owing to the emergence of ...
January 10, 2022 – Akura Medical Inc., a Shifamed portfolio company, announced the closing of its $25 million Series A1 ...
November 12, 2021 — Penumbra Inc. announced that the CHEETAH clinical study of its Indigo System CAT RX Catheter ...
January 8, 2021 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Inari Medical Inc ...
September 25, 2020 — Philips Healthcare launched its QuickClear mechanical thrombectomy system. The compact, single-use ...
July 25, 2019 — Penumbra announced U.S. commercial availability of the Penumbra System’s most advanced technology, the ...
February 12, 2019 — A study presented at the 2018 annual meeting of the Cardiovascular and Interventional Radiology ...
February 5, 2019 — Stroke survivors have better quality of life three months after their stroke if the clot that caused ...
Catheter-based blood clot removal a decade ago was a standard of care for acute coronary revascularization, but declined ...